Effect of intratympanic and retroauricular glucocorticoid injection on sudden deafness

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048762

Enrollment

Unknown

Registered

2021-07-16

Start date

2021-07-16

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden hearing loss

Interventions

Group 1:Intratympanic injection of dexamethasone plus systemic glucocorticoid

Group 2:Retroauricular injection of dexamethasone plus systemic glucocorticoid

Group 3:systemic glucocorticoid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the diagnostic criteria for sudden deafness revised by the American Academy of Otorhinolaryngology Head and Neck Surgery in 2015.

Exclusion criteria

Exclusion criteria: Those with hearing loss due to other causes such as otitis media, Menieres disease, otosclerosis, congenital deafness, presbycusis, vestibular schwannoma, and inner ear malformation.

Design outcomes

Primary

Measure	Time frame
Pure tone average;	—

Countries

China

Contacts

Public ContactXie Wen

The Second Affiliated Hospital of Nanchang University

xiongwenping1982@163.com+86 15879157400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026